Rifadin — Class II drug recall D-886-2013
Terminated recall by Sanofi-Synthelabo, reported 2013-08-21. Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which wa
| Recall number | D-886-2013 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Sanofi-Synthelabo, Laval, Canada |
| Recall initiated | 2013-02-26 |
| Classified | 2013-08-13 |
| Reported by FDA | 2013-08-21 |
| Terminated | 2014-06-06 |
| Countries outside the US | CA |
| Quantity | 998 bottles |
| Reason classes | potency |
| Lot numbers | 3099036 |
| Expiration dates | 2014-03 |
Product
Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, Quebec, Canada H7L4A8, DIN # 02091887
Reason for recall
Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-886-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.